Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) EBT (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of EBT data on record, last reported at -$53.2 million in Q1 2026.

  • On a quarterly basis, EBT fell 75.33% to -$53.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$185.3 million, a 43.74% decrease, with the full-year FY2025 number at -$162.5 million, down 25.39% from a year prior.
  • EBT reached -$53.2 million in Q1 2026 per OLMA's latest filing, down from -$46.1 million in the prior quarter.
  • Over the last five years, EBT for OLMA hit a ceiling of -$20.1 million in Q2 2023 and a floor of -$53.2 million in Q1 2026.
  • A 5-year average of -$32.2 million and a median of -$30.4 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 100.41% in 2022, then soared 39.01% in 2023.
  • Tracing OLMA's EBT over 5 years: stood at -$26.2 million in 2022, then fell by 2.36% to -$26.9 million in 2023, then fell by 24.6% to -$33.5 million in 2024, then tumbled by 37.64% to -$46.1 million in 2025, then fell by 15.49% to -$53.2 million in 2026.
  • Business Quant data shows EBT for OLMA at -$53.2 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.